Evidence map›Paper›PMID 27051552›Full record

ArticleScientifica2016

Role of MMP-2 (-1306 C/T) Polymorphism in Pituitary Adenoma.

Brigita Glebauskiene, Rasa Liutkeviciene, Alvita Vilkeviciute, Loresa Kriauciuniene, Giedrimantas Bernotas, Arimantas Tamasauskas, Dalia Zaliuniene

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientifica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Associations ofBioscience reports · 2017
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Brigita GlebauskieneMedical Academy, Department of Ophthalmology, Lithuanian University of Health Sciences, Eiveniu 2, 50009 Kaunas, Lithuania.ORCID 0000-0002-1259-4999
Rasa LiutkevicieneMedical Academy, Department of Ophthalmology, Lithuanian University of Health Sciences, Eiveniu 2, 50009 Kaunas, Lithuania; Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu 2, 50009 Kaunas, Lithuania.
Alvita VilkeviciuteNeuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu 2, 50009 Kaunas, Lithuania.
Loresa KriauciunieneMedical Academy, Department of Ophthalmology, Lithuanian University of Health Sciences, Eiveniu 2, 50009 Kaunas, Lithuania; Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu 2, 50009 Kaunas, Lithuania.
Giedrimantas BernotasNeuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu 2, 50009 Kaunas, Lithuania; Medical Academy, Department of Neurosurgery, Lithuanian University of Health Sciences, Eiveniu 2, 50009 Kaunas, Lithuania.
Arimantas TamasauskasNeuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu 2, 50009 Kaunas, Lithuania; Medical Academy, Department of Neurosurgery, Lithuanian University of Health Sciences, Eiveniu 2, 50009 Kaunas, Lithuania.
Dalia ZaliunieneMedical Academy, Department of Ophthalmology, Lithuanian University of Health Sciences, Eiveniu 2, 50009 Kaunas, Lithuania.
Lithuanian University of Health Sciences · LT

Funding

Health disparities and agingin societies in transitionR01AG023522 · NIA · UNIVERSITY COLLEGE LONDON · PI MARMOT, MICHAEL G · 2004 to 2008
$2.2M
NIA NIH HHS R01 AG023522Wellcome Trust
6 · The paper itself

Abstract

Purpose. To determine if the frequency of the genotype of MMP-2 (-1306 C/T) Rs243865 has an influence on the development of pituitary adenoma (PA). Methods. The study enrolled n = 84 patients with PA and a random sample of the population n = 318 (reference group). The genotyping test of MMP-2 (-1306 C/T) was carried out using the real-time polymerase chain reaction method. Results. Analysis of MMP-2 (-1306 C/T) gene polymorphism has not revealed any differences in the genotype (C/C, C/T, and T/T) distribution between the PA patients and the reference group (as follows: 50%, 44%, and 6% versus 59.75%, 33.96%, and 6.29%). MMP-2 (-1306) C/C genotype was rarely observed in noninvasive PA compared to healthy controls: 35.1% versus 59.75%; p = 0.0049, as well C/C genotype being more frequently detected in nonrecurrence PA compared to healthy controls: 46.5% versus 59.75%; p = 0.0468. MMP-2 (-1306) C/T genotype was more frequently present in PA females compared to healthy controls females: 49.1% versus 33.66%; p = 0.041. Conclusion. Patients with noninvasive and nonrecurrence pituitary adenoma were the carriers of the C/C genotype significantly more frequently than their control counterparts and the C/T genotype in females was more frequent.

Identifiers

PMID27051552
PMCPMC4804086
OpenAlexW2296982115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.